EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
JUL 2022
TABLES
32
PAGES
125
EDITION
8
PRICE
USD 4950
CODE
MCP10697
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What`s New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Global Bioresorbable Stents Market to Reach $618.8 Million by 2026
Bioresorbable stents represent the latest innovation in angioplasty, the medical procedure wherein a round, tubular, metallic stent is inserted into a clogged artery to open it up and enhance the flow of blood. Technological advancements, over the years, have led to the development of bioresorbable scaffolds made up of polyactides. Also referred to as dissolving stents, biodegradable stents or bioresorbable scaffolds, bioabsorbable stents without any permanent implant, gets resorbed in the body and eventually completely disappear from the body. Bioabsorbable stents have emerged as a successful alternative to the conventional metallic stents that remain permanently in the body, and often cause issues such as late-stent thrombosis, in-stent restenosis and needs antiplatelet therapy for long-term in some patients. Metallic stents may also impede with MRI and CT imaging, and also avert chances of coronary bypass graft surgery. Since, bioabsorbable stents completely dissolve and disappear from the blood vessel following 2 - 4 years of placement, the risks often associated with metallic or drug-eluting stents are also eliminated. As the stent disappears from the artery, the vessel returns to its natural state, resulting in the return of vasoconstriction and vasodilatation.
Growth in the global market is set to be fueled by increasing prevalence of cardiovascular diseases such as peripheral artery and coronary artery diseases, increasing elderly population, and fast increasing obese population. Additional growth factors include an increase in number of PCI procedures performed each year, more patients favoring minimally invasive therapies, higher adoption of these stents by patients and physicians alike, and greater number of clinical trials evaluating the use of bioabsorbable stents. The popularity of bioabsorbable stents is influenced by the elimination of the need to perform stent-in-stent procedures, elimination of the requirement for dual anti-platelet therapies, higher degree of effectiveness in treating coronary artery diseases, and the possibility of achieving accurate stent placement as well as cost-effectiveness of the treatment.
Amid the COVID-19 crisis, the global market for Bioresorbable Stents estimated at US$390.2 Million in the year 2022, is projected to reach a revised size of US$618.8 Million by 2026, growing at a CAGR of 11.8% over the analysis period. Polymer-based Bioresorbable Stents, one of the segments analyzed in the report, is projected to reach US$499.5 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Metal-based Bioresorbable Stents segment is readjusted to a revised 10% CAGR for the next 7-year period. Bioabsorbable polymer stents represent the largest segment as these stents are made using materials that get completely dissolved in the body, and hence find use in procedures with respect to both coronary artery and peripheral artery diseases. Metal-based bioresorbable scaffolds, such as magnesium and iron, are preferred over polymer-based biodegradable stents, due to their superior performance. Magnesium-based bioabsorbable stents minimize thrombogenicity and cause rapid endothelialization, and involve a lesser degradation period.
European Market is Estimated at $213.6 Million in 2022, While Asia-Pacific is Forecast to Reach $159.8 Million by 2026
Bioresorbable Stents market in Europe is estimated at US$213.6 Million in the year 2022. Asia-Pacific is forecast to reach a projected market size of US$159.8 Million by the year 2026 trailing a CAGR of 10.3% over the analysis period. Rest of World is forecast to grow at 11.1% over the analysis period. Europe represents the largest regional market and growth in the region is being spurred by higher prevalence of cardiovascular diseases, an aging population at risk of these diseases, greater awareness with regard to and increased adoption of bioabsorbable stents. The significant demand for technologically advanced treatments for cardiovascular problems boosts usage of bioresorbable stents. Growing awareness with respect to peripheral and coronary artery diseases and an increase in number of people with higher cholesterol levels, a major risk factor for cardiovascular diseases, is helping the demand expand for bioabsorbable stents in Asia-Pacific region.
SELECT PLAYERS
Abbott Laboratories; Arterius Limited; BIOTRONIK SE & Co. KG; Boston Scientific Corporation; Elixir Medical Corp.; Kyoto Medical Planning Co., Ltd.; LEPU MEDICAL TECHNOLOGY CO., LTD.; Meril Life Sciences Pvt. Ltd.; REVA Medical, Inc.
SEGMENTS
» Material (Polymer-based, Metal-based) » Application (Coronary Artery Disease/CAD, Peripheral Artery Disease/PAD) » End-Use (Hospitals, Cardiovascular Centers)
GEOGRAPHIES
» World » Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Bioresorbable Stents – Global Key Competitors Percentage Market Share in 2022 (E) |
Coronary Artery Disease (CAD) – A Perspective |
Causes and Symptoms |
Treatment Options for Coronary Artery Disease |
Percutaneous Coronary Intervention (PCI) |
Coronary Stenting |
Types of Coronary Stents |
Other Treatment Options for Coronary Heart Disease |
Coronary Artery Bypass Grafting (CABG) |
Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) |
TransMyocardial Laser Revascularization (TMR) |
Peripheral Arterial Disease: Understanding the Stealthy Peril |
Treatment for PAD |
Stenting- A Treatment Option for PAD |
BioResorbable Stents – A Prelude |
Bioresorbable Vascular Scaffolds: Advantages and Challenges |
Bioresorbable Stents – A Revolutionary Technology, Riddled with Controversies |
Abbott Stops Sales of the Once Promising ‘Absorb’ Bioresorbable Stents due to Adverse Events |
Impact of Abbott’s Withdrawal of Absorb on the Bioresorbable Stent Industry |
Impact of Covid-19 and a Looming Global Recession |
2020 Marked as a Year of Disruption & Transformation |
EXHIBIT: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022 |
Impact of COVID – 19 on Coronary Stents Market |
Impact on Supply Chain |
Impact of COVID-19 Outbreak on Elective Surgeries |
Global Bioresorbable Stents Market Buckles under COVID-19 Strain |
GLOBAL MARKET OVERVIEW |
Global Bioresorbable Stents Set to Witness Growth in Future |
Europe Dominates, Asia-Pacific Exhibits Fastest Growth |
CAD Constitutes the Leading Application |
Metallic Vs. Polymer-based Stents |
Bioabsorbable Metallic Stents |
Bioabsorbable Polymer Stents |
Disappointing Results by Absorb to Increase Focus on Metallic Stents |
Availability of Alternative Treatments – Hindrance to Market Growth |
Market Challenges |
MARKET OUTLOOK |
Bioresorbable and Integrated Biosensor Technology to Redefine Future of Vascular Stents |
The Future of BRS Technology |
COMPETITION |
Select Approved Bioresorbable Scaffolds |
Select Bioresorbable Stents in Pipeline |
Abbott Revives Bioresorbable Stent Clinical Trials to Evaluate New Esprit Scaffold |
Recent Market Activity |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Polymeric Resorbable Scaffolds Hold a Major Market Share |
The Absorb BRS program |
Desaminotyrosine Polycarbonate-based BRS |
The FANTOM program |
Magnesium-based BRS |
The Magmaris program |
Iron-based BRS |
Global Menace of Coronary Artery Disease (CAD) – A Major Growth Driver |
EXHIBIT: Global Annual Medical Cost of CVD in the United States: 2015-2030 |
EXHIBIT: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others |
Ageing Demographics and Longer Life Expectancy Bolsters Market Growth |
EXHIBIT: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 |
EXHIBIT: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030 |
Rising Middle Class Population Aids Growth |
EXHIBIT: Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P |
Rising Healthcare Expenditure: Opportunities in Store |
EXHIBIT: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023 |
EXHIBIT 3: Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023 |
Risk of CAD in Obesity Offers Prospects for Coronary Stenting |
EXHIBIT: Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P |
Diabetics at Higher Risk of Heart Diseases |
TABLE 15: Diabetes Prevalence Worldwide by Region: Number of Adults (20-79 Years) with Diabetes in 2015 and 2040 |
The Hypertension-Cholesterol Link to Drive Demand |
EXHIBIT: Hypertension Prevalence (%) Worldwide by Region in Male and Females Aged 25+ Years |
Metal Bioresorbable scaffolds Exhibit Improved Performance Compared to Polymer Stents |
Metal Stents Vis-à-Vis Other Stents |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for Bioresorbable Stents by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Bioresorbable Stents by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Polymer-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Polymer-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Metal-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Metal-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Coronary Artery Disease/CAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Coronary Artery Disease/CAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Peripheral Artery Disease/PAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Peripheral Artery Disease/PAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
World Recent Past, Current & Future Analysis for Cardiovascular Centers by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
World 7-Year Perspective for Cardiovascular Centers by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
III. MARKET ANALYSIS |
EUROPE |
Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2021 & 2027 |
Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Europe 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2021 & 2027 |
ASIA-PACIFIC |
Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2021 & 2027 |
Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Asia-Pacific 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2021 & 2027 |
REST OF WORLD |
Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of World 7-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2021 & 2027 |
Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of World 7-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2021 & 2027 |
Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
Rest of World 7-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2021 & 2027 |
IV. COMPETITION |
Total Companies Profiled: 25 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com